ZEPOSIA Drug Patent Profile

Which patents cover Zeposia, and what generic alternatives are available?

Zeposia is a drug marketed by Bristol and is included in one NDA. There are five patents protecting this drug.

This drug has ninety-seven patent family members in twenty-eight countries.

The generic ingredient in ZEPOSIA is ozanimod hydrochloride. One supplier is listed for this compound. Additional details are available on the ozanimod hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Zeposia

Zeposia was eligible for patent challenges on March 25, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 14, 2029. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ZEPOSIA

International Patents:	97
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	12
Clinical Trials:	3
Patent Applications:	70
Drug Prices:	Drug price information for ZEPOSIA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZEPOSIA
What excipients (inactive ingredients) are in ZEPOSIA?	ZEPOSIA excipients list
DailyMed Link:	ZEPOSIA at DailyMed

See drug prices for ZEPOSIA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ZEPOSIA

NDA:

209899

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ZEPOSIA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Colorado, Denver	PHASE4
Geert D'Haens	Phase 4
Bristol-Myers Squibb	Phase 4

See all ZEPOSIA clinical trials

Pharmacology for ZEPOSIA

Drug Class	Sphingosine 1-phosphate Receptor Modulator
Mechanism of Action	Sphingosine 1-Phosphate Receptor Modulators

US Patents and Regulatory Information for ZEPOSIA

ZEPOSIA is protected by six US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol	ZEPOSIA	ozanimod hydrochloride	CAPSULE;ORAL	209899-001	Mar 25, 2020		RX	Yes	No
Bristol	ZEPOSIA	ozanimod hydrochloride	CAPSULE;ORAL	209899-003	Mar 25, 2020		RX	Yes	Yes			Y	Y
Bristol	ZEPOSIA	ozanimod hydrochloride	CAPSULE;ORAL	209899-001	Mar 25, 2020		RX	Yes	No
Bristol	ZEPOSIA	ozanimod hydrochloride	CAPSULE;ORAL	209899-001	Mar 25, 2020		RX	Yes	No			Y	Y

International Patents for ZEPOSIA

When does loss-of-exclusivity occur for ZEPOSIA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Finland

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Netherlands

New Zealand

Norway

Poland

Portugal

Slovenia

South Africa

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZEPOSIA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2010319982
Australia	2010319983
Australia	2010320041
Brazil	112012011427

Supplementary Protection Certificates for ZEPOSIA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2291080	LUC00177	Luxembourg		PRODUCT NAME: OZANIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR OZANIMOD HYDROCHLORIDE; AUTHORISATION NUMBER AND DATE: EU/1/20/1442 20200525
2291080	301065	Netherlands		PRODUCT NAME: OZANIMOD OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER OZANIMODHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/20/1442 20200525
2291080	122020000055	Germany		PRODUCT NAME: OZANIMOD ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE OZANIMODHYDROCHLORID; REGISTRATION NO/DATE: EU/1/20/1442 20200520
2291080	PA2020529	Lithuania		PRODUCT NAME: OZANIMODAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA, YPAC OZANIMODO HIDROCHLORIDAS; REGISTRATION NO/DATE: EU/1/20/1442 20200520

Zeposia market dynamics and financial trajectory: revenue drivers, payer pressure, patent and generic risk, and forward outlook

Last updated: June 10, 2026

Executive summary: Zeposia (ozanimod) generates revenue in multiple sclerosis (MS) and ulcerative colitis (UC) as an oral sphingosine 1-phosphate (S1P) modulator. Near-term financial trajectory is shaped by (1) how quickly prescribers convert eligible patients to ozanimod versus competing S1P agents, (2) channel mix and contracting after formulary updates, (3) intolerance/safety switching within the S1P class, and (4) ongoing margin pressure from higher-cost patient management and contracting rebates. Patent and exclusivity timelines determine the terminal competitive threat window for generic and biosimilar substitution risk, while FDA labeling breadth affects addressable patient volume and line-of-therapy dynamics.

What are the key market dynamics affecting Zeposia (ozanimod) in MS and ulcerative colitis?

Core demand drivers

• Oral convenience versus infusible biologics and many injection regimens.
• S1P-class positioning that competes on efficacy, adherence, and safety profile rather than mechanism novelty.
• Eligibility and sequencing shaped by treatment guidelines and payer step edits (commonly from injectable disease-modifying therapies to oral advanced agents, then to higher-efficacy options based on risk and phenotype).

Competitive pressure points

• Within-class substitutability: Other oral S1P modulators (notably fingolimod, siponimod, ponesimod, and similar agents) can be switched more easily from a payer standpoint than mechanisms with very different monitoring.
• Payer contracting and step therapy: MS and UC formularies frequently use tiering and prior authorization criteria that favor lower net cost or preferred agents.
• Safety-driven utilization: S1P agents face cardiac monitoring and infection risk considerations. Real-world persistence and switching rates often correlate with tolerability and required monitoring workflow.

Commercial levers

• Specialty pharmacy channel and adherence programs reduce drop-off in early treatment months.
• Patient support tied to lab monitoring and starter dosing processes can improve persistence, which directly impacts lifetime value per patient.
• Geographic payer mix matters: net pricing and rebates vary materially by US contract posture versus ex-US market access, where local launch timing and price controls alter uptake curves.

How does payer behavior differ between MS and ulcerative colitis for Zeposia?

• MS: Contracts often anchor around neurologist-driven line progression, with payer incentives to keep patients on preferred oral DMTs once initiated. Claims data show that “early switch” from first oral therapy happens when a patient experiences inadequate response or adverse events.
• UC: Gastroenterology decisioning includes steroid taper goals and endoscopic response targets. Payers can implement step edits that require prior failure of less expensive agents. Once “advanced oral” status is reached, contracting shifts based on cost and outcomes.

What is Zeposia’s financial trajectory: revenue ramp, growth rates, and margin drivers?

Trajectory framework (what moves the numbers)

• New patient starts: Paid in the short term through acquisition and contracting volume, then stabilized by persistence.
• Net price and rebate rate: Changes with formulary outcomes, PBM negotiations, and competitive price floors across the S1P class.
• Mix shift: Higher share of UC starts versus MS can alter margin profile because monitoring intensity, co-therapy patterns, and payer mix differ.
• Persistence and switching: If discontinuation increases due to class safety or infections, revenue per enrolled patient declines, raising customer acquisition cost pressure.

Financial metrics to track

• Net sales by indication (MS vs UC) where reported by the manufacturer.
• Specialty pharmacy fill volume and “days on therapy” proxy from claims.
• Contracted gross-to-net rate and rebate trends.
• Distribution of starts by line of therapy and by payer category.

Key implication for trajectory

• Zeposia’s growth tends to depend less on absolute mechanism differentiation and more on contract stability and real-world persistence relative to competing S1P agents. When preferred status shifts, volume can move quickly.

How does Zeposia compare with competing oral S1P modulators on market share risk?

Competitive set (oral S1P modulators and close comparators)

• Ponesimod
• Siponimod
• Fingolimod (class benchmark; older but often priced aggressively)
• Other MS oral advanced agents outside S1P may substitute when payers push for preferred mechanism classes.

Market share risks

• Formulary substitution: S1P agents compete on a narrow axis of monitoring workflows, contraindications, and tolerability. If a competitor offers a better net cost or payer alignment, Zeposia can lose volume even without a major differentiation gap.
• Safety profile interpretation: In practice, prescribers react to class-level contraindications. Even small differences in monitoring burden can shift switching decisions for patients with comorbidities.
• UC competitive set: UC has more mechanism diversity than MS (including integrin blockers, anti-TNF, IL-12/23, IL-23, JAK inhibitors, and other oral options). Zeposia competes for advanced oral share, which is often capped by payer step therapy.

Which factors drive patient switching away from Zeposia?

• Symptomatic bradycardia or ECG-related issues leading to discontinuation risk.
• Infections or lab abnormalities that trigger dose holds or stopping.
• Insufficient response after induction, particularly in UC where endoscopic endpoints influence continuation decisions.
• Payer-mandated switch to preferred oral agents.

What is the Orange Book status of Zeposia, and what patents protect ozanimod?

Patent estate analysis approach

• Zeposia is typically protected by a mix of:
  1. composition-of-matter patents for ozanimod and/or salts,
  2. formulation and dosage form patents (oral presentation, starter dosing if applicable),
  3. method-of-treatment and use patents in MS and UC, and
  4. manufacturing and process patents.

Actionability constraint

• A precise Orange Book listing requires the exact NDA/BLA identifiers and the active Orange Book entries at the time of analysis. Without that dataset in the prompt, a complete and accurate patent-by-patent table cannot be produced here.

When does Zeposia lose exclusivity in the US, and what is the likely generic entry timeline?

Exclusivity timeline components

• US patent expiration (composition and method-of-use patents create the real barrier).
• Regulatory exclusivity (if applicable under Hatch-Waxman, including application- and marketing- exclusivity categories).
• 5-year bar and 7-year bar interactions depend on the approval history and whether the application is new molecular entity and whether patent carve-outs exist.
• Data exclusivity interacts with Paragraph IV filing timing and settlement structure.

Actionability constraint

• A date-accurate exclusivity timeline requires NDA number, Orange Book publication, and each listed patent’s expiration date and any pediatric exclusivity extensions. Those specifics are not available in the prompt, so a complete calendar cannot be stated.

What Paragraph IV challenges and generic entry risks exist for Zeposia?

Risk pathways

• Paragraph IV filings by generic applicants typically target the controlling Orange Book patents: composition-of-matter, formulation, or method-of-use.
• Settlement agreements (reverse payments) can delay launch and shift entry from a litigated “hard date” to a negotiated date.
• Design-around strategies may target different salt forms, formulation matrices, or method-of-use claims.

Actionability constraint

• To identify actual Paragraph IV filings, litigations, and settlement dates, the underlying Orange Book patent list and any corresponding district court docket events must be cited. The prompt does not provide those records.

What patent litigation affects Zeposia, and how does it impact market access?

Litigation impacts

• Injunction leverage: If asserted patents are found infringed or the case results in a statutory injunction, generic launch can be blocked.
• Claim narrowing: Settlement and non-infringement rulings can preserve exclusivity even when some patents expire earlier than others.
• Timeline compression: Litigation outcomes influence whether entry happens at first available expiration, after final adjudication, or after settlement.

Actionability constraint

• Litigation-specific outcomes require case names, court, docket numbers, and patent assertions not included in the prompt.

How do formulation patents for ozanimod shape competitive barriers?

Typical formulation patent categories

• Extended release or specific dissolution characteristics.
• Covered dosing regimen formats (for example, starter packs and titration sequences if claimed).
• Excipients, film coating, particle-size distribution, and manufacturing process controls.

Commercial implication

• Even when composition patents weaken, formulation protection can delay “generic readiness” by constraining bioequivalence substitutes that would be launched without design-around.

Actionability constraint

• A formulation-protection map requires the exact formulation patent list and claim summaries.

What biosimilar risk exists for Zeposia?

Biosimilar relevance

• Zeposia is a small-molecule drug (ozanimod), not a biologic. That structure generally eliminates biosimilar pathways.

Practical substitution risk

• Competitive risk comes from generics and authorized duplicates, not biosimilars.

What is the US FDA regulatory status of Zeposia, and how does it affect market uptake?

Regulatory status drivers

• Label breadth impacts addressable populations and whether payers treat Zeposia as a first-advanced option or a later-line therapy.
• Safety monitoring requirements influence adoption rate, refill continuity, and payer reimbursement hurdles.
• Postmarketing studies and safety communications can change prescribing patterns even without label withdrawal.

Actionability constraint

• A current status snapshot (current label indications, boxed warnings, REMS presence if any, and recent label changes) requires the FDA product label text or an up-to-date regulatory database reference not provided in the prompt.

How does Zeposia’s commercial performance differ by geography?

Geographic drivers

• US: highest pricing pressure from PBMs and formulary management, but largest base.
• EU/UK: pricing and reimbursement structures often enforce external reference pricing and budget impact constraints that slow uptake.
• Rest of world: launch timing, diagnostic rates, and availability of specialty infusion infrastructure (less relevant for oral drugs) can still shape adoption.

Actionability constraint

• A quantified geography-by-geography sales trajectory requires actual company disclosures or third-party market data not provided in the prompt.

What generic launch scenarios are most likely for Zeposia, and what barriers remain?

Most plausible launch scenarios

• Full generic entry at first actionable expiration of the controlling patents if no settlements block launch.
• Launch after partial patent expiration if remaining method-of-use or formulation patents are not asserted successfully.
• Delayed launch due to ongoing litigation or settlement stay periods.

Remaining barriers after patent erosion

• Lab monitoring requirements and starter dosing workflows can raise switching costs.
• Payer contracting cycles can delay adoption even after legal clearance.

Actionability constraint

• Likely scenarios can’t be ordered by probability without a controlling-patent hierarchy and litigation record.

Key patent estate strength: which claim types likely dominate exclusivity for ozanimod?

Dominant claim types in small-molecule CNS/autoimmune

• Composition-of-matter and salt form claims usually dominate absolute exclusivity.
• Method-of-use claims can remain the last barrier even when composition expires.
• Formulation can dominate if generics require specific release or stability features tied to claim scope.

Actionability constraint

• Determining “which claims dominate” requires the actual patent family tree and claim charts, which are not provided.

Key Takeaways

• Zeposia’s financial trajectory is primarily driven by contracting, patient starts, and persistence relative to competing S1P modulators.
• Competitive pressure in MS is “within-class” and often determined by preferred formulary status and net pricing, not only efficacy.
• In UC, utilization depends on payer step edits and continuation tied to response goals.
• Biosimilar risk is not a factor because ozanimod is a small molecule.
• A complete, date-specific exclusivity and patent-lens analysis requires Orange Book and litigation record inputs that are not present in the prompt.

FAQs

1. Does Zeposia face biosimilar competition, or only generic competition?
2. How do payer step edits in MS and UC typically affect Zeposia adoption speed?
3. What types of safety and monitoring events most commonly drive discontinuation or switching among S1P users?
4. What is the typical role of formulation patents in delaying generic ozanimod entry?
5. How does US net pricing erosion in the S1P class usually change revenue trends for branded oral MS therapies?

References

No sources were provided or cited in the prompt, and no external patent/regulatory/financial datasets were supplied.

DrugChatter Q&A for ZEPOSIA

Generic names for zeposia from authoritative medical sources?
How much does zeposia cost?
How does Zeposia treat MS?